* Note: Prices are in Million (M) USD.
Description:
Maravai Lifesciences Holdings, Inc. is a leading life sciences company headquartered in San Diego, California, specializing in providing essential products and services that facilitate the development of drug therapies, diagnostics, and innovative vaccines. The company plays a crucial role in advancing human disease research, offering a diverse portfolio that addresses the needs of both the pharmaceutical and biotechnology sectors. With a strong commitment to innovation and quality, Maravai is positioned to capitalize on the growing demand for cutting-edge solutions in the life sciences market, both domestically and internationally.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $270 M
Debt : $303 M
EBITDA : $-284 M
Net Debt (Debt - Cash): $33 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 7 overlapping fiscal years (max 20).Average Free Cash Flow: $149 M
Average Revenue: $397 M
Revenue Converted To Free Cash Flow (%): 37.4%
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $259 M
Revenue 5 Years Ago (2019-12-31): $143 M
Total Growth over 5 Years: 81.1%
5-Year Revenue CAGR (Historical): 12.6%
Forward 5-Year CAGR (Tapered): 10.1%
Since historical Revenue CAGR is between 10 - 15, 3 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $138 M
Share Count 5 Years Ago (2020-12-31): $97 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-0.22
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-0.22
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 7 valid ROE years (max 20).Average ROE: 13.7%
Since Average ROE is between 10 - 20, 3 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $3.14
52-Week Low: $1.67
Threshold Price (15% Above 52-Week Low): $1.91
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $1,087 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2023-12-31): $0.44
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 17 points to above Maravai Lifesciences Holdings Inc (MRVI) stock.
Heads up: One or more P/E inputs look exaggerated and may skew the blend.
• RCFC Based PE 37.43 (>2× median)
Further research is recommended; please use your own due diligence.
In such cases, multiplying earnings by the long-run average P/E typically gives a closer, more reliable fair value.
Last 2 Years Avg PE 17.15, Fair Value PE 12, Industry Based PE 15, Growth Based PE 15, RCFC Based PE 37.43, ROE Based PE 13.7, Risk-Free Anchored PE (25% MoS) 18.2. Based on these 7 values, average assigned is 18.35. The fair value of Maravai Lifesciences Holdings Inc (MRVI) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
